Shandong Realcan Pharmaceutical Co Ltd Financial Flexibility Index
Shandong Realcan Pharmaceutical Co Ltd financial flexibility index. Shandong Realcan Pharmaceutical Co Ltd (002589) has a Financial Flexibility Index of 0.00x as of September 2025. Free cash flow of CN¥6.75 Million (operating CF CN¥-15.60 Million minus capex CN¥22.35 Million) represents 0% of total liabilities (CN¥9.87 Billion). Explore Shandong Realcan Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
Financial flexibility index of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025. Historical Financial Flexibility Index trend for Shandong Realcan Pharmaceutical Co Ltd across 18 annual periods. Check Shandong Realcan Pharmaceutical Co Ltd (002589) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shandong Realcan Pharmaceutical Co Ltd Financial Flexibility Index by Year (2008–2025)
Shandong Realcan Pharmaceutical Co Ltd financial flexibility index by year from 2008 to 2025. Year-by-year free cash flow to debt coverage for Shandong Realcan Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Shandong Realcan Pharmaceutical Co Ltd (002589) cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.00x | CN¥40.58 Million | CN¥13.76 Million | CN¥8.95 Billion | ▼ -82.8% |
| 2024 | 0.03x | CN¥271.97 Million | CN¥160.44 Million | CN¥10.32 Billion | ▼ -23.4% |
| 2023 | 0.03x | CN¥380.85 Million | CN¥82.47 Million | CN¥11.07 Billion | ▼ -37.7% |
| 2022 | 0.06x | CN¥694.04 Million | CN¥523.07 Million | CN¥12.58 Billion | ▲ +1.9% |
| 2021 | 0.05x | CN¥904.04 Million | CN¥442.95 Million | CN¥16.70 Billion | ▲ +27.3% |
| 2020 | 0.04x | CN¥920.35 Million | CN¥414.96 Million | CN¥21.65 Billion | ▼ -68.8% |
| 2019 | 0.14x | CN¥3.03 Billion | CN¥2.09 Billion | CN¥22.21 Billion | ▲ +697.0% |
| 2018 | 0.02x | CN¥402.66 Million | CN¥-201.66 Million | CN¥23.53 Billion | ▲ +114.5% |
| 2017 | -0.12x | CN¥-2.04 Billion | CN¥-2.42 Billion | CN¥17.31 Billion | ▲ +33.4% |
| 2016 | -0.18x | CN¥-1.44 Billion | CN¥-1.76 Billion | CN¥8.15 Billion | ▼ -170.4% |
| 2015 | -0.07x | CN¥-356.80 Million | CN¥-466.26 Million | CN¥5.46 Billion | ▼ -1383.3% |
| 2014 | 0.01x | CN¥19.63 Million | CN¥-163.62 Million | CN¥3.85 Billion | ▲ +111.8% |
| 2013 | -0.04x | CN¥-121.36 Million | CN¥-274.46 Million | CN¥2.80 Billion | ▼ -63.7% |
| 2012 | -0.03x | CN¥-58.27 Million | CN¥-170.52 Million | CN¥2.20 Billion | ▲ +91.7% |
| 2011 | -0.32x | CN¥-446.44 Million | CN¥-475.03 Million | CN¥1.40 Billion | ▼ -448.4% |
| 2010 | 0.09x | CN¥108.28 Million | CN¥70.56 Million | CN¥1.18 Billion | ▼ -8.6% |
| 2009 | 0.10x | CN¥80.62 Million | CN¥61.38 Million | CN¥805.78 Million | ▲ +419.2% |
| 2008 | -0.03x | CN¥-18.92 Million | CN¥-49.88 Million | CN¥603.64 Million | — |